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Abstract A Fabry patient with poikilothermia is descri-
bed. Laboratory investigations, neuro-imaging and auto-
nomic function tests did not disclose a cause. Assessment
of intra-epidermal nerve ﬁbre density and quantitative
sensory testing revealed small ﬁbre neuropathy with a
highly impaired cold sensation. We speculate that the
poikilothermia is either caused by a vascular lesion in the
hypothalamus not visible on MRI or by small ﬁbre neu-
ropathy leading to disturbed body temperature perception
and therefore impaired thermoregulation.
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Introduction
Fabry disease (OMIM 301500) is an X-linked glycolipid
storage disease caused by deﬁcient activity of the lysosomal
enzyme a-galactosidase A. This leads to accumulation of
speciﬁc glycosphingolipids and results in multi-system dis-
ease. Early Fabry symptoms and signs are angiokeratomas,
corneal opacities, hypo- or anhidrosis and acroparesthesias.
Later in life renal failure, stroke and cardiomyopathy occur
[1]. Most physicians take care of few Fabry patients, and
some symptoms have only become apparent upon studying
larger patient groups. Hearing loss, for instance, was only
recently shown to occur frequently in these patients [2].
Here, we report on an additional possibly related symptom:
poikilothermia.
Case report
A 38-year-old man was hospitalised because of malaise in
December 2008. He was diagnosed with Fabry disease at
the age of 18 years [3], and at that time he had mild
proteinuria, ankle oedema and left ventricular hypertrophy
with normal cardiac function. In addition, white matter
lesions in the right parietal and temporal lobes on MRI,
sensory hearing loss and tingling paresthesias of the hands
and feet were noted. He has been treated with human
a-galactosidase A (Replagal, Shire Inc.) at a dose of
0.2 mg/kg since 2001. He was stable until March 2008
when he was evaluated because of transient hypoalbumi-
nemia. At this time, hypothermia was noted. A few months
later, he complained of malaise, slurred speech and difﬁ-
culty with walking. At admission, physical examination
revealed a bradyphrenic man with a body temperature of
34C. Repeated measurements over the next weeks showed
temperatures between 32.9 and 34.3C. He declined feeling
cold. Laboratory investigations, including electrolytes,
vitamins, thyroid function and adrenocorticotropic hor-
mones, were unremarkable except for minimal changes in
thyroid hormones [TSH 9.70 mE/L (N = 0.50–5.00), fT4
12.5 pmol/L (N = 10.0–23.0)] with negative anti-thyroxine
peroxidase (aTPO). Structural lesions of the hypothalamus
or its efferent pathways were not seen on cerebral and
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test and Valsalva’s manoeuvre were performed and dem-
onstrated normal cardiovascular autonomic function: the
difference between maximal and minimal heart rates during
the forced breathing test (inspiratory-expiratory difference)
was 9 beats per minute, the highest heart rate in the ﬁrst 15 s
from the onset of standing minus the heart rate at baseline
(DHRmax) was 20 beats per minute, and the ratio between
the highest and lowest heart rate in the ﬁrst 30 s from the
onset of standing (HRmax/HRmin ratio) was 1.3. The
Valsalva manoeuvre showed a normal heart rate and blood
pressure response with a Valsalva ratio of 2.9. Small nerve
ﬁbre function was assessed with quantitative sensory test-
ing: a special device that warms or cools the skin was placed
over the patient’s left hand and right foot. The patient was
asked to press a button as soon as he felt the slightest change
of temperature to warm or cold. These tests showed a highly
impaired cold sensation at the upper and lower limb (see
Fig. 1). A skin biopsy taken 10 cm above the lateral mal-
leolus showed an intraepidermal nerve ﬁbre density (IEN-
FD) of 0.71 ﬁbres/mm which is lower than healthy controls
(median IENFD 8.4 ﬁbres/mm, 0.05 quantile 4.7 ﬁbres/mm
[4]), but similar to other male Fabry patients (median
IENFD 0.5 ﬁbres/mm, unpublished data).
During the following summertime, temperature norma-
lised, and the accompanying symptoms resolved. The
subsequent decrease of body temperature to 34C during
the next winter (2009) and again normalisation during the
summer of 2010 suggested poikilothermia rather than
hypothermia. Poikilothermia is deﬁned as ﬂuctuation in
core temperature of more than 2C due to changes in
ambient temperature. Temperature stress tests were not
performed. Heat stress testing was considered unethical
due to the possible provocation of painful acroparesthesias
that occur in Fabry patients.
To ﬁnd out whether poikilothermia is more prevalent in
Fabrydiseasethanpreviouslyrecognised,wemeasuredbody
temperatures routinely in 60 Fabry patients (22 males, mean
age43 years)attheoutpatientclinic(ambienttemperatureof
21C) from September to December 2009. Only one other
patient (female, 50 years old, known with white matter
lesions, left ventricular hypertrophy and renal failure) had a
temperature below 35C. She also declined feeling cold.
Discussion
Except for heat intolerance due to sweat gland dysfunction,
temperature disturbances have not been reported previ-
ously in Fabry disease. Maintenance of a constant body
temperature is mainly governed by the thermoregulatory
centres in the hypothalamus that contain warm-sensitive
neurons. These neurons are activated by increase of body
temperature and inhibited by input from cold receptors in
the skin [5]. Integration of temperature information leads to
heat loss responses or to heat conservation and production.
Aside from hypothalamic lesions (e.g. vascular, multiple
sclerosis and trauma), old age and thyroid disorders are the
most common causes of impaired thermoregulation pre-
senting symptoms as described in our patient (malaise,
bradyphrenia, slurred speech and disturbed gait). Auto-
nomic neuropathy may contribute to disturbed thermoreg-
ulation by impaired control of cutaneous circulation. We
studied the autonomic nervous system in our patient
showing normal cardiovascular autonomic function. This is
in line with our recent study in 48 Fabry patients, where the
generally accepted assumption that Fabry patients suffer
from overt autonomic neuropathy was rejected [6]. In that
paper, we suggested that symptoms and signs compatible
with autonomic dysfunction in Fabry patients are mainly
caused by end-organ failure due to continuous accumula-
tion of glycosphingolipids. However, other investigators
argue that functional autonomic neuropathy is a key feature
of Fabry disease due to accumulation of glycosphingolipids
in central and peripheral autonomic structures. A recent
report on cardiovascular responses to orthostatic challenge
in Fabry patients using spectral analysis revealed a reduced
sympathetic activation and a limited cardiovagal with-
drawal upon standing, suggesting subtle dysfunction of the
autonomic nervous system [7]. However, none of the
Fig. 1 Quantitative sensory testing results at the lower limb.
Quantitative sensory testing consisted of thermal detection and
thermal pain thresholds. These tests were performed using a TSA
2001-II thermal sensory testing device. Normative values have been
well established in our laboratory. Each test was done four times. This
ﬁgure shows that our patient has a highly impaired cold sensation at
the lower limb: a temperature decrease to 0C was not perceived as
cold or pain. Warm sensation was normal. The horizontal lines
represent normative values. Values with exclamatory mark indicate
abnormal value
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whereas this is seen invariably in patients with autonomic
neuropathy due to other diseases accompanied by periph-
eral neuropathies [8]. Abnormalities at the level of the
heart, the vascular walls or the baroreceptors themselves
could have accounted for the abnormal cardiovascular
responses in that study.
Common causes of poikilothermia are hypothalamic
lesions or thyroid disorders. In 1996, four women with
poikilothermia were described [9]. It was concluded that in
these subjects, who had normal blood pressure responses to
standing up and Valsalva manoeuvre, poikilothermia had to
be attributed predominantly to disorders of the central
thermoregulatory pathways, being a trauma, a tumour and
an empty sella. Possibly, the poikilothermia in our patient is
also caused by a central nervous system abnormality.
Wecannot exclude forexample thatthe white matter lesions
found elsewhere in the brain of our patient point to a
small localised vascular episode in the appropriate part
of the hypothalamus not visible on MRI. The minimal
changes in thyroid hormones are a consequence rather than
a cause of the poikilothermia, as shown by its spontaneous
normalisation.
Finally, we propose that the small nerve ﬁbre dysfunc-
tion could underly the abnormal temperature regulation.
Quantitative sensory testing and skin biopsy results showed
the presence of a severe small ﬁbre neuropathy, which is a
common ﬁnding in Fabry disease [10]. These tests were
done during summertime when body temperature and
thyroid hormones had normalised spontaneously. Possibly,
the conduction of ‘cold’ information by small ﬁbres from
peripheral thermoreceptors to the hypothalamus is insufﬁ-
cient, while increases in body temperature are detected
normally by the hypothalamic warm-sensitive neurons.
This imbalance may lead to impaired feedback and there-
fore to a lower body temperature, especially during the
cold winter time. However, if this was the true cause of
poikilothermia in our patient, it is remarkable that poikil-
othermia has not been noted in other equally affected Fabry
patients with small ﬁbre neuropathy.
Conclusion
Poikilothermia in Fabry disease may have various causes.
In our patient, the disturbed thermoregulation is either
caused by a vascular lesion in the hypothalamus not visible
on MRI or by his small ﬁbre neuropathy with highly
impaired cold sensation leading to impaired feedback and a
low body temperature. More clinical observations and
studies are awaited.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Desnick RJ, Ioannou YA, Eng ME (2001) a-Galactosidase A
deﬁciency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS,
Valle D (eds) The metabolic and molecular bases of inherited
disease, 8th edn. McGraw-Hill, New York, pp 3733–3774
2. Germain DP, Avan P, Chassaing A, Bonﬁls P (2002) Patients
affected with Fabry disease have an increased incidence of pro-
gressive hearing loss and sudden deafness: an investigation of
twenty-two hemizygous male patients. BMC Med Genet 3:10
3. Knol IE, Ausems MG, Lindhout D, van Diggelen OP, Verwey H,
Davies J, Ploos van Amstel JK, Poll-The BT (1999) Different
phenotypic expression in relatives with Fabry disease caused by a
W226X mutation. Am J Med Genet 82:436–439
4. Bakkers M, Merkies IS, Lauria G, Devigili G, Penza P, Lombardi
R, Hermans MC, van Nes SI, de Baets M, Faber CG (2009)
Intraepidermal nerve ﬁbre density and its application in sar-
coidosis. Neurology 73:1142–1148
5. Benarroch EE, Low PA, Fealey RD (2008) Autonomic regulation
of temperature and sweating. In: Low PA, Benarroch EE (eds)
Clinical autonomic disorders, 3rd edn. Lippincott Williams and
Wilkins, Baltimore, pp 68–73
6. Biegstraaten M, van Schaik IN, Wieling W, Wijburg FA, Hollak
CEM (2010) Autonomic neuropathy in Fabry disease: a pro-
spective study using the Autonomic Symptom Proﬁle and car-
diovascular autonomic function tests. BMC Neurol 10:38
7. Hilz MJ, Marthol H, Schwab S, Kolodny EH, Brys M, Stemper B
(2010) Enzyme replacement therapy improves cardiovascular
responses to orthostatic challenge in Fabry patients. J Hypertens
28:1438–1448
8. Freeman R (2007) Autonomic peripheral neuropathy. Neurol Clin
25:277–301
9. MacKenzie MA, Wollersheim HCH, Lenders JWM, Hermus
ARMM, Thien T (1996) Skin blood ﬂow and autonomic reac-
tivity in human poikilothermia. Clin Auton Res 6:91–97
10. Luciano CA, Russell JW, Banerjee TK, Quirk JM, Scott LJ,
Dambrosia JM, Barton NW, Schiffmann R (2002) Physiological
characterization of neuropathy in Fabry’s disease. Muscle Nerve
26:622–629
Clin Auton Res (2011) 21:177–179 179
123